e-ESO Podcasts

143 Episoder

1. Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

   Publisert: 2.2.2023
2. Basics of prostate cancer pathology

   Publisert: 26.1.2023
3. Oligometastaic breast cancer

   Publisert: 19.1.2023
4. Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias

   Publisert: 12.1.2023
5. Summary/Review - Reporting Guidelines - CHEERS

   Publisert: 6.12.2022
6. Role of immunotherapy in head and neck cancer

   Publisert: 1.12.2022
7. AYAs with cancer: the right to be forgotten

   Publisert: 24.11.2022
8. Summary/Review - Reporting Guidelines - SQUIRE

   Publisert: 17.11.2022
9. Male breast cancer

   Publisert: 10.11.2022
10. Summary/Review - Reporting Guidelines - SRQR

    Publisert: 3.11.2022
11. Summary/Review - Reporting Guidelines - AGREE

    Publisert: 27.10.2022
12. Breast Cancer: Frequently Asked Questions and Answers

    Publisert: 20.10.2022
13. The role of Medical Physicist in Oncology

    Publisert: 13.10.2022
14. How to approach to breast cancer patient who had not received neoadjuvant chemo and staged T2NO postoperatively?

    Publisert: 6.10.2022
15. Parp inhibitors in ovarian cancer

    Publisert: 29.9.2022
16. Primary endocrine resistant in recurrent locoregional only Breast cancer (role of endocrine therapy)

    Publisert: 22.9.2022
17. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

    Publisert: 15.9.2022
18. The use of Lutetium PSMA as treatment in mCRPC – in what sequence and how to best select patients

    Publisert: 8.9.2022
19. Use of Medical Cannabis in Oncology. Knowledges and attitudes among oncologist and patient.

    Publisert: 1.9.2022
20. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

    Publisert: 27.7.2022